Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. - Wikidata - wikimedia - TriplyDB

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.

http://www.wikidata.org/entity/Q36363225

about

Active surveillance for nonmuscle invasive bladder cancer Non-muscle invasive bladder cancer risk stratification New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer Performance of survivin mRNA as a biomarker for bladder cancer in the prospective study UroScreen Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis.Identification of S100A8-correlated genes for prediction of disease progression in non-muscle invasive bladder cancer Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer.Identification of C16orf74 as a marker of progression in primary non-muscle invasive bladder cancer.CCL21/CCR7 interaction promotes cellular migration and invasion via modulation of the MEK/ERK1/2 signaling pathway and correlates with lymphatic metastatic spread and poor prognosis in urinary bladder cancer.Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients IL-8 as a urinary biomarker for the detection of bladder cancer.Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis Chromosomal alterations in exfoliated urothelial cells from bladder cancer cases and healthy men: a prospective screening study Urothelial carcinomas: a focus on human epidermal receptors signaling Three-gene signature predicts disease progression of non-muscle invasive bladder cancer.FAM70B as a Novel Prognostic Marker for Cancer Progression and Cancer-Specific Death in Muscle-Invasive Bladder Cancer.Pretreatment levels of serum osteoprotegerin and p53 protein and urine telomerase as prognostic factors affecting survival in Egyptian bladder cancer patients Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer.GOLPH3 is a potential therapeutic target and a prognostic indicator of poor survival in bladder cancer treated by cystectomy.The pathology of bladder cancer: An update on selected issues.The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder.Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer.Survival in bladder and renal cell cancers is familial.Superficial bladder cancer: part 1. Update on etiology, classification and natural history.UBE2C is a marker of unfavorable prognosis in bladder cancer after radical cystectomy.Predicting survival after radical cystectomy for bladder cancer.Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer Epigenetic markers as promising prognosticators for bladder cancer.Combining a molecular profile with a clinical and pathological profile: biostatistical considerations Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression.Novel role of MDA-9/syntenin in regulating urothelial cell proliferation by modulating EGFR signaling.Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome Epigenetic biomarkers in urothelial bladder cancer.Urinary proteomic profiling for diagnostic bladder cancer biomarkers.Urothelial carcinoma of the bladder: definition, treatment and future efforts.Urothelial cancers: using biology to improve outcomes.DNA methylation-based biomarkers in bladder cancer.Increased SPHK1 expression is associated with poor prognosis in bladder cancer.

P2860

Q26744158-D7F7E9C0-2A00-4B80-908F-4A03CA6B3345 Q26775984-7DAF536E-44FE-4260-8A29-F52B0A101ACB Q26798006-B2450F39-DEE2-48A0-A9DE-C5B61320EDCD Q28482379-DD818E69-BE41-4055-990D-1A26D306F7FC Q30439612-566AF4F9-CFF9-4C42-92CC-24CF55D96D89 Q30446429-65D4CDFD-D39E-4D42-8817-A6CE8693654C Q33526078-898FDDEB-F96D-4239-BD0B-24116F5E9580 Q33650639-F2C34F33-A951-4B53-BC92-1C9CE08FBFDC Q33778439-ECB33A4C-CEAD-4555-956D-6B7AA1E44294 Q33784739-4762DC79-C6AE-494B-A7BD-D05F9196721C Q33788042-B9C2002C-850B-413B-8F7F-337EB3FB1C59 Q34042341-801F6A45-9CA4-49FE-A5D0-5EB2BF88983E Q34258579-D60A5D00-CCBD-4563-82C5-60A4363AC282 Q34512129-B18F72CC-57D7-42EE-A9A9-1B513721CFA0 Q34587111-F665F65F-BE30-44E3-ACBF-BDC485B668BE Q35172558-3B455C4F-10EE-463E-9EF8-46CB9B5E89D5 Q36121198-734F4755-B87C-4DF3-A4CC-DC98F6311EEC Q36284742-95320779-4F79-47B6-ACB4-0356B16C95E6 Q36502817-0A28CE96-5549-4D18-887D-68F35E6B3FF9 Q36529700-7725704D-B65F-40D5-8031-4CA1EF477626 Q36544805-76CC3CC6-5EFA-436E-80B1-B549AC91949D Q36552067-EB09A0AA-CCB6-4D28-8813-444226A1FE3A Q36611805-3EBF9C70-A1E3-42A7-BD25-1EAFC7E56A65 Q36614005-B1A40C4C-2094-4A40-B86B-1927AA7D788A Q36662145-D7B070C2-7B73-473E-882C-50B6ED1C19E1 Q36689131-F56E5EA3-3B6A-4AC6-AA7E-A87903178FD8 Q36956211-BDD9E79A-B1E5-4BE9-836B-4F609A9FB241 Q37103989-26B0F445-616A-4BE6-AD9C-6D8909B9D125 Q37172493-75C2047B-C1A9-4DA7-8F07-1ED045F073EC Q37249752-493434E1-652D-4AAD-89FB-2B37ACC29F6E Q37279010-0C72014B-1F27-42B8-ADB1-AD34D79B75DE Q37308146-6CBBD6D2-DA62-414F-878B-9E48DE9D54B5 Q37412627-1DDF0CEB-8A48-43C0-B4AF-56635B8BFB4E Q37424793-B73DF2A2-15E2-4B8D-BDB8-1F7B966E2E72 Q37451558-E6BAD447-EB19-45F8-8C41-0AD210BD47F8 Q37610310-DB3E4019-1DFA-40CD-82FB-BCF512E86368 Q37944437-E87E50BF-F1E4-4AD1-8BAE-A3E70006C446 Q37965638-7D7AEDEE-4F0F-4BD1-AD89-AAEF23D24BB3 Q38102879-2DE9D013-D4E3-4D48-BD03-4205EB5174C9 Q38394714-B151D450-2E30-4E85-B736-6B7DDB3290DC

P2860

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.

http://www.wikidata.org/entity/Q36363225

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Prognostic markers for bladder ...... anel on bladder tumor markers.

@ast

Prognostic markers for bladder ...... anel on bladder tumor markers.

@en

type

label

Prognostic markers for bladder ...... anel on bladder tumor markers.

@ast

Prognostic markers for bladder ...... anel on bladder tumor markers.

@en

prefLabel

Prognostic markers for bladder ...... anel on bladder tumor markers.

@ast

Prognostic markers for bladder ...... anel on bladder tumor markers.

@en

P1433

Q36363225-2611C492-8A21-4DC2-BCEB-FB88A206C87B

P1476

Q36363225-53B5236E-78E9-4A4D-A3C9-C59C404DD7EE

P2093

Q36363225-1542B712-C627-4572-8131-4112D808BB97

Q36363225-4EA96984-DF49-4E61-8956-274573F17B7D

Q36363225-4FB4E80F-DE04-47A3-8551-D013C248AF7F

Q36363225-5256295C-6E55-47B0-9B02-0D68FB6F63BA

Q36363225-564FFAC9-3091-4D4A-B863-1653E6AC55BF

Q36363225-907B709F-2564-46DE-BCB6-242E39BEEFFD

Q36363225-AFBAF007-3E30-4E33-872F-EFE3E7C6E786

Q36363225-B911204C-9F2A-489C-826F-CDF668F76CDB

Q36363225-B9F6E443-DDEB-41E1-BEC1-E7B7995CFC00

Q36363225-C49553EF-841D-4C95-8793-53BEC8CA9EB2

P304

Q36363225-493F59E8-A491-4765-A753-0770A81F48C2

P31

Q36363225-D1F12911-CD96-4CC5-90ED-F2D1DE398C08

P356

Q36363225-6D7D7E73-E086-401D-8395-D4BFBD3AFA5B

P407

Q36363225-3D6479F9-5EB1-4F05-91D1-6DFD1D5A3C0E

P433

Q36363225-8A087D47-2277-43D3-918E-94100792AABA

P478

Q36363225-3B2E4D06-0A08-4C39-B6CB-6EE18F1F107B

P577

Q36363225-CB1C8A40-F40C-46E8-9BF9-018F595B2959

P698

Q36363225-8B53E90F-5076-46D4-B97D-92245AAD307B

P356

J.UROLOGY.2005.08.065

P1433

P1476

Prognostic markers for bladder ...... anel on bladder tumor markers.

@en

P2093

Aldo V Bono

http://www.w3.org/2001/XMLSchema#string

Bernd J Schmitz-Dräger

http://www.w3.org/2001/XMLSchema#string

Edward Messing

http://www.w3.org/2001/XMLSchema#string

George P Hemstreet

http://www.w3.org/2001/XMLSchema#string

H Barton Grossman

http://www.w3.org/2001/XMLSchema#string

Jack A Schalken

http://www.w3.org/2001/XMLSchema#string

Michael J Droller

http://www.w3.org/2001/XMLSchema#string

Michael Marberger

http://www.w3.org/2001/XMLSchema#string

Peter Goebell

http://www.w3.org/2001/XMLSchema#string

Robert H Getzenberg

http://www.w3.org/2001/XMLSchema#string

P304

64-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.UROLOGY.2005.08.065

http://www.w3.org/2001/XMLSchema#string

P407

P433

6 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16399416

http://www.w3.org/2001/XMLSchema#string